As of 2024-12-14, the EV/EBITDA ratio of Celldex Therapeutics Inc (CLDX) is -9.64. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CLDX's latest enterprise value is 1,649.30 mil USD. CLDX's TTM EBITDA according to its financial statements is -171.06 mil USD. Dividing these 2 quantities gives us the above CLDX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 15.5x - 19.0x | 16.6x |
| Forward P/E multiples | 15.4x - 26.1x | 20.2x |
| Fair Price | (39.37) - (48.50) | (46.96) |
| Upside | -254.9% - -290.9% | -284.8% |
| Date | EV/EBITDA |
| 2024-12-11 | -10.00 |
| 2024-12-10 | -10.07 |
| 2024-12-09 | -10.03 |
| 2024-12-06 | -10.17 |
| 2024-12-05 | -9.89 |
| 2024-12-04 | -10.10 |
| 2024-12-03 | -9.96 |
| 2024-12-02 | -10.35 |
| 2024-11-29 | -10.43 |
| 2024-11-27 | -10.60 |
| 2024-11-26 | -10.17 |
| 2024-11-25 | -10.70 |
| 2024-11-22 | -10.27 |
| 2024-11-21 | -9.96 |
| 2024-11-20 | -10.03 |
| 2024-11-19 | -9.47 |
| 2024-11-18 | -8.83 |
| 2024-11-15 | -8.92 |
| 2024-11-14 | -9.77 |
| 2024-11-13 | -10.20 |
| 2024-11-12 | -10.26 |
| 2024-11-11 | -9.95 |
| 2024-11-08 | -9.96 |
| 2024-11-07 | -10.05 |
| 2024-11-06 | -10.50 |
| 2024-11-05 | -9.65 |
| 2024-11-04 | -9.63 |
| 2024-11-01 | -9.75 |
| 2024-10-31 | -9.89 |
| 2024-10-30 | -10.00 |
| 2024-10-29 | -10.20 |
| 2024-10-28 | -10.63 |
| 2024-10-25 | -10.24 |
| 2024-10-24 | -10.70 |
| 2024-10-23 | -10.91 |
| 2024-10-22 | -10.94 |
| 2024-10-21 | -10.91 |
| 2024-10-18 | -10.74 |
| 2024-10-17 | -10.93 |
| 2024-10-16 | -11.31 |
| 2024-10-15 | -11.19 |
| 2024-10-14 | -11.53 |
| 2024-10-11 | -11.93 |
| 2024-10-10 | -11.30 |
| 2024-10-09 | -11.46 |
| 2024-10-08 | -11.63 |
| 2024-10-07 | -11.58 |
| 2024-10-04 | -11.67 |
| 2024-10-03 | -11.75 |
| 2024-10-02 | -11.50 |